JP6804133B2 - アデノウイルスおよび対応するプラスミドの作製方法 - Google Patents

アデノウイルスおよび対応するプラスミドの作製方法 Download PDF

Info

Publication number
JP6804133B2
JP6804133B2 JP2016537434A JP2016537434A JP6804133B2 JP 6804133 B2 JP6804133 B2 JP 6804133B2 JP 2016537434 A JP2016537434 A JP 2016537434A JP 2016537434 A JP2016537434 A JP 2016537434A JP 6804133 B2 JP6804133 B2 JP 6804133B2
Authority
JP
Japan
Prior art keywords
adenovirus
site
gene
restriction
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016537434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017501695A5 (enExample
JP2017501695A (ja
Inventor
クレアー ノエル ブラウン，アリス
クレアー ノエル ブラウン，アリス
ニコールソン，タマラ
Original Assignee
サイオクサス セラピューティクス リミテッド
サイオクサス セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/072919 external-priority patent/WO2015059303A1/en
Application filed by サイオクサス セラピューティクス リミテッド, サイオクサス セラピューティクス リミテッド filed Critical サイオクサス セラピューティクス リミテッド
Publication of JP2017501695A publication Critical patent/JP2017501695A/ja
Publication of JP2017501695A5 publication Critical patent/JP2017501695A5/ja
Application granted granted Critical
Publication of JP6804133B2 publication Critical patent/JP6804133B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016537434A 2013-12-23 2014-12-23 アデノウイルスおよび対応するプラスミドの作製方法 Active JP6804133B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1322851.5A GB201322851D0 (en) 2013-12-23 2013-12-23 Method
GB1322851.5 2013-12-23
PCT/EP2014/072919 WO2015059303A1 (en) 2013-10-25 2014-10-24 Oncolytic adenoviruses armed with heterologous genes
EPPCT/EP2014/072919 2014-10-24
PCT/EP2014/079162 WO2015097220A1 (en) 2013-12-23 2014-12-23 A method of making adenovirus and corresponding plasmids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020197533A Division JP7104994B2 (ja) 2013-12-23 2020-11-27 アデノウイルスおよび対応するプラスミドの作製方法

Publications (3)

Publication Number Publication Date
JP2017501695A JP2017501695A (ja) 2017-01-19
JP2017501695A5 JP2017501695A5 (enExample) 2018-02-08
JP6804133B2 true JP6804133B2 (ja) 2020-12-23

Family

ID=50114629

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016537434A Active JP6804133B2 (ja) 2013-12-23 2014-12-23 アデノウイルスおよび対応するプラスミドの作製方法
JP2020197533A Active JP7104994B2 (ja) 2013-12-23 2020-11-27 アデノウイルスおよび対応するプラスミドの作製方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020197533A Active JP7104994B2 (ja) 2013-12-23 2020-11-27 アデノウイルスおよび対応するプラスミドの作製方法

Country Status (10)

Country Link
US (1) US10472648B2 (enExample)
JP (2) JP6804133B2 (enExample)
KR (1) KR20160102024A (enExample)
CN (1) CN106062199B (enExample)
AU (1) AU2014372562B2 (enExample)
CA (1) CA2934015A1 (enExample)
GB (1) GB201322851D0 (enExample)
IL (1) IL246235B (enExample)
SG (1) SG11201604801WA (enExample)
WO (1) WO2015097220A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201802728T4 (tr) 2013-10-25 2018-03-21 Psioxus Therapeutics Ltd Heterolog genlerle donatılmış onkolitik adenovirüsler.
BR122018004815A2 (pt) 2015-04-30 2019-09-10 Psioxus Therapeutics Ltd adenovírus oncolítico que codifica proteína b7
EA201891022A1 (ru) * 2015-12-17 2019-01-31 Псайоксус Терапьютикс Лимитед Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
CN119614520A (zh) 2016-08-29 2025-03-14 阿卡米斯生物公司 携带双特异性t细胞衔接器的腺病毒
GB201713765D0 (en) * 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
US20200017862A1 (en) * 2017-03-07 2020-01-16 University Of North Carolina Charlotte Systems and methods for single-strand break signaling and repair in a cell-free system
CN120796389A (zh) * 2017-05-26 2025-10-17 埃皮森特Rx股份有限公司 携带转基因的重组腺病毒
WO2018220207A1 (en) * 2017-06-01 2018-12-06 Psioxus Therapeutics Limited Oncolytic virus and method
SG11202003058UA (en) * 2017-10-16 2020-04-29 Glaxosmithkline Biologicals Sa Replication competent adenoviral vectors
CN108424932B (zh) * 2018-03-13 2021-01-05 北京多赢时代转化医学研究院 重组溶瘤腺病毒、用于制备该重组溶瘤腺病毒的重组溶瘤腺病毒载体及其构建方法和应用
GB201814141D0 (en) * 2018-08-30 2018-10-17 Univ Oxford Innovation Ltd Method and compositions for producing a virus
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
CN113186151A (zh) * 2021-03-03 2021-07-30 郑州大学 一种提高腺病毒产毒能力的单克隆细胞、细胞库及制备方法
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2342396A1 (en) 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
CN1221666C (zh) * 2003-09-02 2005-10-05 广东省人民医院 腺病毒穿梭质粒及其构建方法
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
WO2005118825A2 (en) 2004-05-26 2005-12-15 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
EP1819823A2 (en) * 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
WO2007027860A2 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
WO2008080003A2 (en) 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
EP2606127B1 (en) * 2010-08-16 2019-03-20 Salk Institute For Biological Studies Adenoviral assembly method
EP2619312A1 (en) 2010-09-24 2013-07-31 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies
CN102586327B (zh) * 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
CA2931322A1 (en) 2013-11-22 2015-05-28 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
BR122018004815A2 (pt) 2015-04-30 2019-09-10 Psioxus Therapeutics Ltd adenovírus oncolítico que codifica proteína b7

Also Published As

Publication number Publication date
AU2014372562B2 (en) 2020-11-26
CA2934015A1 (en) 2015-07-02
CN106062199B (zh) 2019-12-03
JP2021040651A (ja) 2021-03-18
JP7104994B2 (ja) 2022-07-22
WO2015097220A1 (en) 2015-07-02
AU2014372562A1 (en) 2016-07-21
SG11201604801WA (en) 2016-07-28
IL246235A0 (en) 2016-07-31
CN106062199A (zh) 2016-10-26
IL246235B (en) 2020-02-27
KR20160102024A (ko) 2016-08-26
JP2017501695A (ja) 2017-01-19
GB201322851D0 (en) 2014-02-12
US20160319304A1 (en) 2016-11-03
US10472648B2 (en) 2019-11-12

Similar Documents

Publication Publication Date Title
JP6804133B2 (ja) アデノウイルスおよび対応するプラスミドの作製方法
JP4216350B2 (ja) 動物細胞感染用の組換えｄｎａウイルスベクター
KR102243243B1 (ko) 신규한 cho 통합 부위 및 이의 용도
JP3770333B2 (ja) 組換えｄｎａウイルスおよびその製造方法
EP1015620B1 (en) Dual selection cassette and plasmids containing same
US6838285B2 (en) Site specific recombinase based method for producing adenoviral vectors
US20240018546A1 (en) Single cycle replicating adenovirus vectors
JP2019530467A (ja) 安全性向上のための自己制限Ｃａｓ９回路網（ＳＬｉＣＥＳ）プラスミドおよびそのレンチウイルス系
WO2005121343A1 (en) Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof
CN104212802B (zh) 一种肿瘤细胞广谱高活性启动子及其用途
CN111492056A (zh) 用于细胞的遗传修饰的非整合型dna载体
JP4386971B2 (ja) スプライシング配列を含んでなる組換えアデノウイルスベクター
CN117165611A (zh) 一种构建mRNA体外转录模板的骨架
WO2015024484A1 (zh) 一种新型狂犬病疫苗及其制备方法
JP7688697B2 (ja) ＣＲＩＳＰＲ／ＣＡＳ媒介ｉｎ ｖｉｖｏ末端分離による組換えアデノウイルスのレスキュー
CA2594375A1 (en) Bovine adenovirus type 3 genome
JP2004519201A (ja) キメラアデノウイルスベクター
JP5260815B2 (ja) 組換えアデノウイルスおよびアデノウイルスライブラリーの調製
EP3087187B1 (en) A method of making adenovirus and corresponding plasmids
KR20220055399A (ko) 세포질에서 자가 전사가 가능한 mRNA를 제공하는 RNA/DNA 시스템
KR20230028860A (ko) 세포질에서 자가 전사가 가능하고 cDdRp mRNA를 제공하는 RNA/DNA 시스템
JP4288259B2 (ja) 動物細胞感染用の組換えｄｎａウイルスベクター
KR20230127069A (ko) 세포질에서 자가 전사가 가능한 mRNA를 제공하는 RNA/DNA 시스템
AU2002327645A1 (en) Site-specific recombinase based method for producing adenoviral vectors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201127

R150 Certificate of patent or registration of utility model

Ref document number: 6804133

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250